-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On March 3, NMPA's official website showed that Yangzijiang Pharmaceutical's sodium potassium magnesium sulfate oral solution and levofloxacin sodium chloride injection were approved for marketing, which are deemed to have passed the consistency evaluation
.
According to data from Minet.
com, in 2020, the sales of levofloxacin injection in public medical institutions in China will exceed 4.
6 billion yuan, and the market for sodium, potassium, and magnesium sulfate oral solution is still blank
.
Magnesium Sodium Potassium Sulfate Oral Concentrated Solution is a new type of bowel cleansing preparation.
It has the characteristics of small dosage, high patient tolerance and good bowel cleansing effect.
It is the recommended drug in the European and American bowel cleansing preparation guidelines
.
At present, the commonly used intestinal cleaning preparation drugs in domestic clinics include compound polyethylene glycol electrolyte powder and sodium phosphate oral solution
.
On January 30, Jichuan Pharmaceutical's concentrated solution of magnesium sodium and potassium sulfate for oral administration was approved for marketing, becoming the first imitation in China
.
This product was approved by Yangzijiang Pharmaceuticals, the second domestic company
.
Levofloxacin is a quinolone antibiotic, suitable for respiratory system infections, urinary system infections, reproductive system infections, skin and soft tissue infections, intestinal infections, sepsis and other infections caused by sensitive bacteria
.
According to data from Minet.
com, in 2020, the sales of terminal levofloxacin injection in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) exceeded 4.
6 billion yuan; in the first half of 2021, its sales exceeded 2 billion yuan.
Yuan, an increase of 4.
58% year-on-year, and the market share of Yangzijiang Pharmaceuticals is close to 30%
.
Sales of terminal levofloxacin injection in Chinese public medical institutions (unit: ten thousand yuan) Source: Minet Sexual evaluation
.
Yangzijiang is the 9th company that has passed the evaluation of this variety
.
Up to now, 96 varieties of Yangzijiang Pharmaceutical have passed or deemed to pass the consistency evaluation, of which 40 are injections
.
.
.
According to data from Minet.
com, in 2020, the sales of levofloxacin injection in public medical institutions in China will exceed 4.
6 billion yuan, and the market for sodium, potassium, and magnesium sulfate oral solution is still blank
.
Magnesium Sodium Potassium Sulfate Oral Concentrated Solution is a new type of bowel cleansing preparation.
It has the characteristics of small dosage, high patient tolerance and good bowel cleansing effect.
It is the recommended drug in the European and American bowel cleansing preparation guidelines
.
At present, the commonly used intestinal cleaning preparation drugs in domestic clinics include compound polyethylene glycol electrolyte powder and sodium phosphate oral solution
.
On January 30, Jichuan Pharmaceutical's concentrated solution of magnesium sodium and potassium sulfate for oral administration was approved for marketing, becoming the first imitation in China
.
This product was approved by Yangzijiang Pharmaceuticals, the second domestic company
.
Levofloxacin is a quinolone antibiotic, suitable for respiratory system infections, urinary system infections, reproductive system infections, skin and soft tissue infections, intestinal infections, sepsis and other infections caused by sensitive bacteria
.
According to data from Minet.
com, in 2020, the sales of terminal levofloxacin injection in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) exceeded 4.
6 billion yuan; in the first half of 2021, its sales exceeded 2 billion yuan.
Yuan, an increase of 4.
58% year-on-year, and the market share of Yangzijiang Pharmaceuticals is close to 30%
.
Sales of terminal levofloxacin injection in Chinese public medical institutions (unit: ten thousand yuan) Source: Minet Sexual evaluation
.
Yangzijiang is the 9th company that has passed the evaluation of this variety
.
Up to now, 96 varieties of Yangzijiang Pharmaceutical have passed or deemed to pass the consistency evaluation, of which 40 are injections
.
.
